



ELSEVIER

Prostaglandins & other Lipid Mediators 77 (2005) 235–248

---

---

PROSTAGLANDINS  
& other  
LIPID MEDIATORS

---

---

Review

## Distinguishing phospholipase A<sub>2</sub> types in biological samples by employing group-specific assays in the presence of inhibitors

Karin Killermann Lucas, Edward A. Dennis\*

*University of California, San Diego School of Medicine, Department of Chemistry, Biochemistry and Pharmacology, 9500 Gilman Drive, La Jolla, San Diego, CA 92093 0601, USA*

Received 14 February 2005; accepted 15 February 2005

Available online 10 May 2005

---

### Abstract

This manuscript reviews and updates radiolabel-based enzyme assays designed to distinguish the activity of phospholipase A<sub>2</sub> (PLA<sub>2</sub>) types in biological samples. This approach should be useful in lipidomics studies. The assays were originally designed to differentiate between Group IVA cytosolic PLA<sub>2</sub> (GIVA cPLA<sub>2</sub>), Group VIA calcium-independent PLA<sub>2</sub> (GVIA iPLA<sub>2</sub>), Group IIA secreted PLA<sub>2</sub> (GIIA sPLA<sub>2</sub>) and Group V secreted PLA<sub>2</sub> (GV sPLA<sub>2</sub>). The specificity of these assays has now been confirmed using purified, recombinant human PLA<sub>2</sub>s and the utility of these assays is demonstrated with rat spinal cord homogenate as an example of a biological tissue sample of interest to the neuroscience community. Modifications to the original assays by the addition of group-specific inhibitors are presented to ensure the specificity of the assays and to further differentiate between recently identified PLA<sub>2</sub>s. Specific tests are suggested to confirm the specificity of each assay. Additionally, it was discovered that one commonly used GIVA cPLA<sub>2</sub>/GVIA iPLA<sub>2</sub> inhibitor, methyl arachidonyl fluorophosphonate (MAFP) from one commercial source, was found to inhibit GIIA sPLA<sub>2</sub> and GV sPLA<sub>2</sub>, but not GIVA cPLA<sub>2</sub>, presumably due to oxidation of the compound during shipment, resulting in a different molecule with altered specificity.

© 2005 Elsevier Inc. All rights reserved.

**Keywords:** Lipidomics; Phospholipase A<sub>2</sub>; MAFP; BEL; Indoxam; Dole assay; PLA<sub>2</sub> activity assay; PIP<sub>2</sub>

---

\* Corresponding author. Tel.: +1 858 534 3055; fax: +1 858 534 7390.

E-mail address: edennis@ucsd.edu (E.A. Dennis).

## Contents

1. Introduction .....	236
2. Materials and methods .....	237
2.1. Materials .....	237
2.2. Phospholipase A <sub>2</sub> enzymes .....	237
2.3. Preparation of rat spinal cord homogenate and rat cerebral spinal fluid .....	238
2.4. Phospholipase A <sub>2</sub> assays .....	238
2.4.1. Lipid preparation .....	238
2.4.2. Assay conditions .....	238
2.4.3. Data analysis .....	239
3. Results and discussion .....	239
3.1. Group-specific assays on pure enzymes .....	239
3.2. Proof of principle: testing a biological sample .....	239
3.3. Specificity improved assays .....	242
3.3.1. GIVA cPLA <sub>2</sub> .....	242
3.3.2. GVI iPLA <sub>2</sub> .....	243
3.3.3. sPLA <sub>2</sub> .....	244
3.4. Important precautions .....	245
4. Conclusion .....	246
Acknowledgements .....	247
References .....	247

---

## 1. Introduction

Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) catalyzes the hydrolysis of fatty acids from the *sn*-2 position of phospholipids. The release of fatty acids including arachidonic acid (AA) and lysophospholipids from the cell membrane by PLA<sub>2</sub> activity leads to a cascade of lipid second messengers that regulates a wide variety of physiological responses. Interest in the PLA<sub>2</sub> field has increased in the past decade with the discovery of the important role of lipid messengers in diseases such as cancer [1–3] and atherosclerosis [4,5]. While lipidomics approaches should help elucidate the intricate relationships of the numerous lipid messengers, the ability to also block and measure the activity of the specific PLA<sub>2</sub> enzymes that initiate lipid second messenger release should aid in lipidomics studies.

In 1999, our laboratory published a manuscript on group-specific assays describing four specific PLA<sub>2</sub> assays [6] that were designed to distinguish between the four major mammalian PLA<sub>2</sub> enzymes that had been identified at that time. The assays took advantage of differences in preferred lipid substrate and activators, calcium dependence and susceptibility to disulfide bond reduction to distinguish between the Group IVA cytosolic PLA<sub>2</sub> (GIVA cPLA<sub>2</sub>), the Group VIA calcium-independent PLA<sub>2</sub> (GVIA iPLA<sub>2</sub>) and two secreted sPLA<sub>2</sub>s (GIIA and GV sPLA<sub>2</sub>). The power of these assays lies in their use in determining the activity of each of these enzymes in a biological sample.

In the decade following the research that contributed to the manuscript's preparation, major advances have occurred in the PLA<sub>2</sub> field. Two new paralogs of the GIVA cPLA<sub>2</sub> were

Download English Version:

<https://daneshyari.com/en/article/9894072>

Download Persian Version:

<https://daneshyari.com/article/9894072>

[Daneshyari.com](https://daneshyari.com)